These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 21942930)

  • 1. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
    Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
    Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
    Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D;
    Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.
    Schinstock CA; Bentall AJ; Smith BH; Cornell LD; Everly M; Gandhi MJ; Stegall MD
    Am J Transplant; 2019 Jun; 19(6):1671-1683. PubMed ID: 30412654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
    Kulkarni S; Kirkiles-Smith NC; Deng YH; Formica RN; Moeckel G; Broecker V; Bow L; Tomlin R; Pober JS
    Am J Transplant; 2017 Mar; 17(3):682-691. PubMed ID: 27501352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases.
    Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA
    Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated rejection despite inhibition of terminal complement.
    Bentall A; Tyan DB; Sequeira F; Everly MJ; Gandhi MJ; Cornell LD; Li H; Henderson NA; Raghavaiah S; Winters JL; Dean PG; Stegall MD
    Transpl Int; 2014 Dec; 27(12):1235-43. PubMed ID: 24990476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
    Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH;
    Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation.
    Schwotzer N; Paganetti G; Barchi M; Perrottet N; Aubert V; Sadallah S; Rotman S; Venetz JP; Matter M; Golshayan D; Pascual M
    Xenotransplantation; 2020 Jul; 27(4):e12630. PubMed ID: 32698246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept.
    Favi E; Cresseri D; Perego M; Ikehata M; Iesari S; Campise MR; Morello W; Testa S; Sioli V; Mattinzoli D; Longhi E; Del Gobbo A; Castellano G; Ferraresso M
    Clin Immunol; 2024 Jul; 264():110240. PubMed ID: 38734036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience.
    Kleiboeker HL; Prom A; Paplaczyk K; Myers CN
    Ann Pharmacother; 2024 Sep; 58(9):947-955. PubMed ID: 37994573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement inhibition as potential new therapy for antibody-mediated rejection.
    Eskandary F; Wahrmann M; Mühlbacher J; Böhmig GA
    Transpl Int; 2016 Apr; 29(4):392-402. PubMed ID: 26474721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation.
    Yerly P; Rotman S; Regamey J; Aubert V; Aur S; Kirsch M; Hullin R; Pascual M
    Xenotransplantation; 2022 Jan; 29(1):e12726. PubMed ID: 35001433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-Based Therapy in the Management of Antibody-Mediated Rejection.
    Bhalla A; Alachkar N; Alasfar S
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):138-148. PubMed ID: 32553246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation.
    West-Thielke P; Progar K; Campara M; Jasiak N; Gallon L; Tang I; Spaggiari M; Tzvetanov I; Benedetti E
    Transplant Proc; 2018; 50(1):66-69. PubMed ID: 29407333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
    Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
    Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
    Orandi BJ; Zachary AA; Dagher NN; Bagnasco SM; Garonzik-Wang JM; Van Arendonk KJ; Gupta N; Lonze BE; Alachkar N; Kraus ES; Desai NM; Locke JE; Racusen LC; Segev DL; Montgomery RA
    Transplantation; 2014 Oct; 98(8):857-63. PubMed ID: 25121475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.